I only got in as of yesterday at open, can't complain about my one day return, and intend to stay for some time! As far as I could find from news searches, there was nothing to account for the jump. I suspect that it may have in part been a reaction to the previous day's -2 5/8, which was also not a response to any news, which is in fact why I finally took the plunge. I expect an excellent recovery in the biotechs and small cap techs for much of the rest of the year, in spite of interest rate uncertainties this month, and PCOP appears to have an excellent position from which to make large gains, especially if they reach new milestones with existing partners or gain new partnerships. I'm also encouraged by the small level of institutional holdings, about 21% according to a report that I found (it did not give the date for this percentage however), which provides further upside as managers look for promising companies to get into.
I'm glad to see some quick responses to the thread. As I pointed out, I don't have any special knowledge of the biotech industry and am neither an organic chemist, biologist or physician (I'm actually a geochemist who in part consults for the mining and minerals exploration industry, fortunately not for Bre-X!, and in part runs a research program at the University of British Columbia)). From this perspective, I can comprehend many general aspects of the scientific process involved, but not necessarily the aspects specific to PCOP (therefore the reason I opened the thread).
Thanks also to the second respondent for clarifying some points. I did not have my research materials with me when I wrote the first entry, and I was afraid that I would make some errors. But work was slow and I thought I would start it anyway.
Two things that I would find of interest are a discussion of competition in comb. chem., and also how PCOP might interact with genomics companies like AFFX.
Good trading. |
